Full Breakdown
OpenEvidence Secures $250 Million in Funding, Doubling Valuation to $12 Billion
1/21/2026, 8:27:15 PM
Overview of OpenEvidence's Growth
OpenEvidence, an artificial intelligence startup often referred to as "ChatGPT for doctors," has successfully raised $250 million in a Series D funding round, bringing its valuation to $12 billion. Founded in 2022 by Daniel Nadler and Zachary Ziegler, the Miami-based company has rapidly expanded its reach within the healthcare sector, having raised nearly $700 million in total funding since its inception. The latest funding round was co-led by Thrive Capital and DST Global, with participation from notable investors including Google Ventures, Nvidia, and Sequoia Capital.
Funding Timeline and Financial Performance
OpenEvidence's valuation has seen significant growth over a short period. Initially valued at $1 billion in February 2025 after raising $75 million, the company’s worth surged to $6 billion by October 2025 following a $200 million funding round. The recent funding round not only doubled its valuation but also highlighted the increasing investor confidence in healthcare AI solutions. OpenEvidence reported over $100 million in annual revenue last year, primarily generated through organic growth and advertising.
Unique Positioning in the Healthcare AI Market
OpenEvidence differentiates itself from competitors by exclusively training its AI models on data from reputable medical journals, such as the New England Journal of Medicine and the Journal of the American Medical Association. This approach aims to provide high-quality, evidence-based medical information to doctors, contrasting with other AI models that may rely on less reliable sources from the internet. Nadler emphasized the importance of these partnerships, stating, "The licensing partnerships early on were very critical," as they established a foundation of trusted content for the platform.
Criticism and Industry Challenges
Despite its rapid growth, OpenEvidence faces scrutiny regarding the sustainability of its business model. A report from Silicon Valley Bank raised concerns about whether companies like OpenEvidence could deliver on their high valuations through advertising and software-as-a-service models. Additionally, as larger AI firms like OpenAI and Anthropic enter the healthcare space with their own offerings, OpenEvidence must navigate a competitive landscape that is increasingly crowded.
Future Directions and Innovations
Looking ahead, OpenEvidence aims to develop "medical super-intelligence" by coordinating specialized AI models that function similarly to expert care teams in hospitals. Nadler noted that the company is in the early stages of this evolution, stating, "We're in the first 2% of this wave because no one has scratched the surface of 'super intelligence'." OpenEvidence has already begun forming strategic partnerships, such as with the National Comprehensive Cancer Network, to enhance its offerings in oncology.
Verbatim Quotes
- “Health care is the largest segment of the real economy,” — Daniel Nadler, Co-founder and CEO of OpenEvidence
- “Even if someone copied the playbook today, they'd still be far behind because it's not just the partnerships, it's the real-world usage data.” — Daniel Nadler
- “If a doctor tried to stay current by reading only the new evidence in the top 10 medical journals and only the most recent changes to their specialty guidelines, it would take nine hours of their day, each day,” — Daniel Nadler
OpenEvidence's rapid ascent in the healthcare AI sector reflects a broader trend of increasing investment in specialized medical applications, positioning it as a key player in the evolving landscape of healthcare technology.
